Want to see IN:EMCURE full AI Analyst Report?
EMCURE Stock Chart & Stats
₹1345.35
₹31.90(2.25%)
At close: 4:00 PM EST
₹1345.35
₹31.90(2.25%)
Day’s Range― - ―
52-Week Range₹1,260.10 - ₹2,047.40
Previous CloseN/A
Volume1.63K
Average Volume (3M)197.42K
Market Cap
₹366.79B
Enterprise Value₹255.38K
Total Cash (Recent Filing)₹6.02B
Total Debt (Recent Filing)₹16.59B
Price to Earnings (P/E)36.2
Beta0.76
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)22.89
Shares Outstanding189,680,150
10 Day Avg. Volume24,274
30 Day Avg. Volume197,417
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.11
Price to Sales (P/S)3.29
P/FCF Ratio61.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹2,320.00Price Target Upside72.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)60.84
Revenue Forecast (FY)₹104.41B
Bulls Say, Bears Say
Bulls Say
Revenue & Profitability GrowthSustained top-line expansion with mid-teens operating margins and a ~10% net margin indicates the business is scaling while maintaining operating profitability. That combination supports reinvestment in brands, manufacturing capacity and R&D, and underpins durable earnings quality over 2–6 months.
Conservative Leverage & Improving ROEA conservative leverage profile together with improved ROE to the high-teens signals stronger capital efficiency and financial flexibility. This balance sheet posture supports strategic capex, geographic expansion or bolt-on deals without immediately stressing credit metrics over the medium term.
Diversified Pharma Revenue ModelMultiple revenue pillars — branded domestic sales, export markets, contract manufacturing and API supply — reduce single-market concentration and allow revenue stability across cycles. Diverse channels help sustain cash flow and growth as regulatory approvals and partner execution scale over months.
Bears Say
Weak Cash ConversionFCF covering only ~58% of net income and a year‑over‑year decline implies earnings are not fully translating into cash. That constrains self-funding of capex, dividends or working capital, increasing reliance on external financing and raising medium‑term liquidity and execution risk.
Gross Margin VolatilityNotable swings in gross margin undermine predictability of core profitability and complicate budgeting and pricing strategy. If volatility stems from input costs, product mix, or one‑offs, it raises the risk that operating margins may fluctuate and forecasting accuracy will be impaired over coming quarters.
Rising Absolute DebtAn increase in absolute debt, despite conservative leverage ratios, raises interest expense and refinancing exposure if cash conversion weakens. Growing debt levels can compress financial flexibility and raise funding costs, heightening balance sheet risk during industry or operational stress.
Emcure Pharmaceuticals Limited News
EMCURE FAQ
What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?
Emcure Pharmaceuticals Limited lowest stock price was ₹1260.10 and its highest was ₹2047.40 in the past 12 months.
What is Emcure Pharmaceuticals Limited’s market cap?
Emcure Pharmaceuticals Limited’s market cap is ₹366.79B.
When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?
Emcure Pharmaceuticals Limited’s upcoming earnings report date is Nov 05, 2026 which is in 80 days.
How were Emcure Pharmaceuticals Limited’s earnings last quarter?
Emcure Pharmaceuticals Limited released its earnings results on Aug 06, 2026. The company reported ₹15.4 earnings per share for the quarter, beating the consensus estimate of ₹12.6 by ₹2.8.
Is Emcure Pharmaceuticals Limited overvalued?
According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued.
Does Emcure Pharmaceuticals Limited pay dividends?
Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3.6 which represents an annual dividend yield of 0.16%. See more information on Emcure Pharmaceuticals Limited dividends here
What is Emcure Pharmaceuticals Limited’s EPS estimate?
Emcure Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emcure Pharmaceuticals Limited have?
Emcure Pharmaceuticals Limited has 189,680,150 shares outstanding.
What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?
Emcure Pharmaceuticals Limited reported an EPS of ₹15.4 in its last earnings report, beating expectations of ₹12.6. Following the earnings report the stock price went down -1.174%.
Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:EMCURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
EMCURE Stock 12 Month Forecast
Average Price Target
₹2,320.00
▲(72.45% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Lupin Limited
―